Reuters logo
UPDATE 1-Ariad says partner Merck to acquire cancer treatment
May 5, 2010 / 11:40 AM / in 8 years

UPDATE 1-Ariad says partner Merck to acquire cancer treatment

* Ariad to receive $50 mln upfront payment from Merck

* Says Merck will have developing and marketing rights

* Ariad shares up 9 pct pre-market

May 5 (Reuters) - Ariad Pharmaceuticals Inc ARIA.O said its partner Merck & Co Inc (MRK.N) will acquire all development and marketing rights of their experimental cancer treatment, ridaforolimus.

As per the agreement, Ariad will receive an upfront cash payment of $50 million from Merck. Ariad will also be reimbursed for expenses it has incurred on ridaforolimus since January 1, which is estimated to be around $19 million.

Ariad will also be eligible to receive up to $514 million in regulatory and sales milestones based on the successful development and commercialization of ridaforolimus in multiple indications.

This includes $65 million in milestones associated with the potential sarcoma indication, which is currently in late-stage trial, the companies said in a statement.

Merck will fund 100 percent of future development, manufacturing and commercialization of the program, effective immediately, the companies said.

Shares of Ariad were trading up about 9 percent at $4.15 Wednesday in pre-market trade. They had closed at $3.81 Tuesday on Nasdaq.

Merck shares closed at $35.81 in the New York Stock Exchange. (Reporting by Krishnakali Sengupta in Bangalore; Editing by Roshni Menon)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below